India's Natco Pharma rises after US FDA closes inspection without urging action

Shares of Natco Pharma NATP.NS rise 3% to 883.20 rupees

U.S. Food and Drug Administration (FDA) completed inspection at its Hyderabad plant, classifying the facility as Voluntary Action Indicated (VAI)

VAI indicates the agency is not prepared to take or recommend any administrative or regulatory action, per the FDA website

Co had said inspection was "procedural" and that it was confident it could address it comprehensively

Stock, on avg, rated "hold" with median PT 983.50 rupees - data compiled by LSEG

Stock down 36% YTD